Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim for Neutropenia Prevention in mTNBC Patients on Sacituzumab Govitecan
NCT06616987Phase 2Recruiting
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pegfilgrastim in neutropenia. Started Jul 2025; status: recruiting.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT06616987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616987.